5 High Dividend Yield Stocks to Buy for a Stable Portfolio in 2H 2026

This reads less like a yield trade and more like a quality-factor rotation signal. The common thread is balance-sheet durability plus cash conversion, which matters most if earnings revisions flatten and investors pay up for downside protection; in that setting, the upside is usually multiple resilience rather than explosive EPS acceleration.

The cleaner relative winners are FAST, GD and DGX: each has a reinvestment runway that can compound through a slower macro tape, while the closest public peers tend to be more exposed to either procurement cyclicality or pricing pressure. FAST’s moat is strongest if digital penetration keeps rising faster than company-average sales, because that deepens switching costs and can quietly take share from slower industrial distributors; GD’s visibility is only as good as budget execution, so a continuing CR or procurement delay is the main near-term falsifier. DGX is the most underrated consolidator in the group because hospital outreach and consumer testing can improve mix even when organic volumes are mediocre.

The weak link is TXRH: it looks defensive on the surface, but restaurant margins are still a wage-and-food inflation call dressed up as an income stock. UNH is the highest-quality compounder, but also the most policy-sensitive; if medical cost trends reaccelerate or reimbursement pressure worsens, the defensive premium can unwind fast. Contrarian view: the market may be underestimating how crowded 'quality dividend' positioning has become after a long stretch of factor preference; if rates fall quickly and cyclicals stabilize, the relative outperformance window could be shorter than consensus expects.